ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Furthermore, the company's Residential Care Software segment saw an 8% increase due to the adoption of digital solutions in homecare settings. ResMed’s adjusted gross margin improved by 230 ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

Analyst Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD – ...

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 millionNote: A webcast of ...

ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst ...

Learn more about whether Penumbra, Inc. or ResMed Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.43 in the first ...

ResMed has a minority stake in Nyxoah who are developing a neurostimulation implant to treat OSA. Although we see little near ...